Evidence map›Paper›PMID 14722301›Full record

ArticleJournal of virology2004

Selection of TAR RNA-binding chameleon peptides by using a retroviral replication system.

Baode Xie, Valerie Calabro, Mark A Wainberg, Alan D Frankel

Abstract read
In one paragraph

Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Baode XieDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, California 94143-2280, USA.
Valerie Calabro
Mark A Wainberg
Alan D Frankel
Jewish General Hospital · CAUniversity of California, San Francisco · US

Funding

ACTIVITY AND INHIBITION OF THE TAT PROTEIN FROM HIVR01AI029135 · NIAID · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI FRANKEL, ALAN D · 1989 to 2010
$2.8M
NIAID NIH HHS R01 AI029135NIAID NIH HHS R01 AI29135
6 · The paper itself

Abstract

The interaction between the arginine-rich motif (ARM) of the human immunodeficiency virus (HIV) Tat protein and TAR RNA is essential for Tat activation and viral replication. Two related lentiviruses, bovine immunodeficiency virus (BIV) and Jembrana disease virus (JDV), also require Tat ARM-TAR interactions to mediate activation, but the viruses have evolved different RNA-binding strategies. Interestingly, the JDV ARM can act as a "chameleon," adopting both the HIV and BIV TAR binding modes. To examine how RNA-protein interactions may evolve in a viral context and possibly to identify peptides that recognize HIV TAR in novel ways, we devised a retroviral system based on HIV replication to amplify and select for RNA binders. We constructed a combinatorial peptide library based on the BIV Tat ARM and identified peptides that, like the JDV Tat ARM, also function through HIV TAR, revealing unexpected sequence characteristics of an RNA-binding chameleon. The results suggest that a retroviral screening approach may help identify high-affinity TAR binders and may provide new insights into the evolution of RNA-protein interactions.

Indexed as

Amino Acid SequenceAnimalsArginineCattleCell LineCombinatorial Chemistry TechniquesGene Products, tatHIV-1HIV Long Terminal RepeatHumansLentivirusMiceMolecular Sequence DataNucleic Acid ConformationPeptide LibraryPeptidesArginineGene Products, tatPeptide LibraryPeptidesRNA-Binding ProteinsRNA, Viraltat Gene Products, Human Immunodeficiency VirusTrans-Activation Responsive RNA-Binding Protein

Identifiers

PMID14722301
PMCPMC321383
OpenAlexW2166752964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.